Best Practices in Action
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
PROTALIX BIOTHERAPEUTICS, INC. (Exact Name of Registrant As Specified in Its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) PROTALIX BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Florida 65-0643773 State or other jurisdiction (I.R.S. Employer of incorporation or organization Identification No.) 2 Snunit Street Science Park POB 455 Carmiel, Israel 20100 (Address of principal executive offices) (Zip Code) 972-4-988-9488 Registrant’s telephone number, including area code Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common stock, par value $0.001 per share NYSE MKT Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. -
Opko Health: the Placebo Effect
Opko Health: The Placebo Effect Lakewood Capital Management December 2013 /placebo effect/ (plah-se’bo ĕ-fekt’), noun [L.]: 1. the beneficial effect that occurs following a treatment administered to a group that arises simply from that group’s faith or preconceptions that the treatment will work. 2. an ineffectual treatment intended to deceive the recipient. Table of Contents A.) Executive Summary ................................................................................................... 1 B.) A Dizzying History Of Deals and Disappointment .................................................. 8 C.) Poor Financial Results… Yet A Soaring Market Capitalization ............................. 15 D.) Latin American Drug Distribution ........................................................................... 17 E.) Exploratory Alzheimer’s Diagnostic ...................................................................... 18 F.) Claros Diagnostics ................................................................................................... 19 G.) 4Kscore™ Exploratory Prostate Cancer Screening Test ......................................... 22 H.) Rayaldy .................................................................................................................... 26 I.) Prolor Biotech .......................................................................................................... 30 J.) A Web Of Stock Promotion ..................................................................................... 33 K.) Insider Share Purchases -
Signature Redacted
VC Funding Elements in US-Israel Case and Application to China-Korea By Anna Lee B.S. Business Administration, Finance and Corporate Management California State University, East Bay, 2012 SUBMITTED TO THE MIT SLOAN SCHOOL OF MANAGEMENT IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE IN MANAGEMENT STUDIES AT THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY JUNE 2017 @2017 Anna Lee. All rights reserved. The author hereby grants to MIT permission to reproduce and to distribute publicly paper and electronic copies of this thesis document in whole or in part in any medium now known or hereafter created. Signature redacted Signature of Author: V MIT Sloan S chool of Management May 12, 2017 Signature redacted Certified by: Jake Cohen Seniot Associate Dean for Undergraduate and Master's Programs Thesis Supervisor Signature redacted Accepted by: MASSA H IsENSTITUTE Rodrigo Verdi OFTEHNLGY Associate Professor of Accounting JUN 2 0 2017 Program Director, M.S. in Management Studies Program LIBRARIES ARCHIVES 77 Massachusetts Avenue Cambridge, MA 02139 MITLibraries http://Iibraries.mit.edu/ask DISCLAIMER NOTICE Due to the condition of the original material, there are unavoidable flaws in this reproduction. We have made every effort possible to provide you with the best copy available. Thank you. The images contained in this document are of the best quality available. Th c ppo n K> 2 VC Funding Elements in US-Israel Case and Application to China-Korea By Anna Lee Submitted to MIT Sloan School of Management on May 12, 2017 in Partial Fulfillment of the requirements for the Degree of Master of Science in Management Studies. -
Life Sciences in Israel
Inspiration Invention Innovation Life Sciences in Israel www.investinisrael.gov.il Life Sciences in Israel Table of Contents Israel: A Powerhouse of Opportunities Israel: A Powerhouse of Opportunities .................................................3 Over the last decade, Israel has introduced a wealth of groundbreaking Why Israel’s Life Sciences? and valuable innovations in life sciences. Israel’s life sciences sector is Israel’s Life Science Sectors ..................................................................4 supported by a strong foundation of academic excellence, including some Over 1,000 life sciences Medical Devices of the world’s leading research institutes, renowned R&D facilities and companies - biopharma and Biopharmaceuticals cutting-edge medical centers. Bolstered by a highly skilled workforce, a medical devices Healthcare IT flourishing high-tech environment, and an entrepreneurial spirit, Israeli companies have been joined by leading multinationals in making Israel a Over 1/3 of LS Start-Ups Israel’s Biomedical Engineering: recognized force in the industry worldwide. Global giants, including Johnson already generate revenue. Spotlight on Stem Cell Research .........................................................11 & Johnson, Perrigo, GE Healthcare, Phillips Medical, Abbott Laboratories, Source of numerous Merck Serono and Sanofi together with local companies such as Teva, itself blockbuster drugs such Israel’s Life Sciences Competitive Edge ..............................................15 a multinational company,